Arrowhead Research
ARWR
272 hedge funds and large institutions have $2.54B invested in Arrowhead Research in 2024 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 98 increasing their positions, 86 reducing their positions, and 34 closing their positions.
87% more call options, than puts
Call options by funds: $35.5M | Put options by funds: $19M
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
14% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 86
0.61% more ownership
Funds ownership: 78.08% → 78.69% (+0.61%)
0% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 34
1% less funds holding
Funds holding: 274 → 272 (-2)
8% less capital invested
Capital invested by funds: $2.77B → $2.54B (-$226M)
Top Buyers
| 1 |
UBS AM
Chicago,
Illinois
|
+$33.3M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$19.7M |
| 3 |
Morgan Stanley
New York
|
+$16.7M |
| 4 |
Jane Street
New York
|
+$14M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$10.3M |
Top Sellers
| 1 |
O
OrbiMed
New York
|
-$21.2M |
| 2 |
State Street
Boston,
Massachusetts
|
-$17.8M |
| 3 |
Pictet Asset Management
Carouge,
Switzerland
|
-$11.9M |
| 4 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$7.96M |
| 5 |
JP Morgan Chase
New York
|
-$7.92M |
ARWR Hedge Fund Activity: Q2 2024 in Review
272 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Arrowhead Research (ARWR) for Q2 2024, worth a combined $2.54B — down 8.2% from $2.77B a quarter earlier.
Fund positioning in ARWR was balanced in Q2 2024: 34 funds opened new positions, 34 closed out, 98 added to existing stakes and 86 trimmed.
The largest buyer was UBS AM, adding an estimated $33.3M. The largest seller was OrbiMed, exiting entirely with an estimated $21.2M sold.
- 272 institutional investors held Arrowhead Research (ARWR) as of Q2 2024, down from 274 in Q1 2024.
- Funds reported $2.54B of Arrowhead Research stock for Q2 2024, down 8.2% quarter-over-quarter.
- 34 funds opened new Arrowhead Research positions in Q2 2024 and 34 closed out, a net change of 0 holders.
- The largest Arrowhead Research buyer in Q2 2024 was UBS AM, an estimated $33.3M added.
- The largest Arrowhead Research seller in Q2 2024 was OrbiMed, an estimated $21.2M sold.
Based on aggregated 13F filings for Q2 2024.